Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-10883059

RESUMO

Having developed a non-insulin-dependent diabetes mellitus (NIDDM) syndrome model in the rabbit using Wirsung duct ligation, it appeared interesting to use it to study the relationship between glycemia and the plasma levels of TXA(2)and PGI(2), and of some other biochemical parameters such as cholesterol, triglycerides, alkaline phosphatase and transaminases. A comparative study was carried out in the sham-operated rabbits (controls, C) and those having their pancreatic duct ligatured (NIDDM, D) at 15, 30, 40, 50 and 60 days post-ligation. On the 40th days, whereas in the controls, glycemia was 1.17 +/- 0.04 g.l(-1), it reached a maximum of 4.62 +/- 0.76 g.l(-1)(25.40 mM) in the NIDDMs. No significant modification was observed either in cholesterolemia or in triglyceridemia in either group. The GOT and GPT were highly increased, from 11.50 +/- 4.00 IU. l(-1)and 27.00 +/- 1.50 IU.l(-1)(C) to 37.50 +/- 5.64 IU.l(-1)(P<0. 001) and 58.50 +/- 7.50 IU.l(-1)(D) (P<0.001) in the NIDDM group, suggesting that hyperglycemia occurred simultaneously with the degeneration of the pancreatic tissue. In parallel, in D rabbits, the plasma levels of TXB(2)and 6 keto PGF(1alpha)were augmented to 68.22 +/- 6.20 pg.ml(-1)versus 22.49 +/- 5.74 pg.ml(-1)(C) (P<0.001), and 127.11 +/- 14.39 pg.ml(-1)versus 48.65 +/- 4.51 pg.ml(-1)(C) (P<0. 001) respectively. Statistical studies showed a significant correlation (P<0.05 and <0.02) between glycemia and the biosynthesis of eicosanoids under study. Moreover, 25 mM was found to be the threshold level of glucose excess essential to increase the TXA(2)and PGI(2)biosynthesis significantly. This supports the results obtained by other authors studying the action of glucose on phospholipase activity and consequent eicosanoid production.


Assuntos
Diabetes Mellitus Experimental/sangue , Epoprostenol/sangue , Tromboxano A2/sangue , 6-Cetoprostaglandina F1 alfa/sangue , Fosfatase Alcalina/sangue , Animais , Glicemia/metabolismo , Proteínas Sanguíneas/metabolismo , Colesterol/sangue , Diabetes Mellitus Tipo 2/etiologia , Modelos Animais de Doenças , Epoprostenol/biossíntese , Hiperglicemia/sangue , Ligadura , Ductos Pancreáticos/cirurgia , Inibidores da Agregação Plaquetária/sangue , Coelhos , Tromboxano A2/biossíntese , Tromboxano B2/sangue , Fatores de Tempo , Transaminases/sangue
2.
Artigo em Inglês | MEDLINE | ID: mdl-3140251

RESUMO

The effects of 2-(2 dimethylaminoethyl) 5-benzylidene 6-methyl (2H,4H)-3-pyridazinone (III) were studied on the biosynthesis of TXA2 and PGI2 in vitro the TXA2 and PGI2 synthetase activity of heart tissue. Biosyntheses of TXA2 and PGI2 were carried out using arachidonic acid as a substrate and horse platelet and aorta microsomes as sources of TXA2 and PGI2 synthetases respectively. TXB2 and 6-keto PGF1 alpha were determined by RIA. III--did not significantly modify either the biosynthesis of PGI2 in vitro or the PGI2 synthetase activity of heart tissue. did not significantly inhibit TXA2 biosynthesis in vitro but markedly reduced the TXA2 synthetase activity of heart tissue: for a microsomal fraction concentration of 100 micrograms protein, the ID50 was 6.37 X 10(-5) M +/- 1.29 X 10(-8) M. Thus III behaves as a specific inhibitor of the TXA2 synthetase activity of heart tissue and could have a beneficial use in therapeutics.


Assuntos
Compostos de Benzil/farmacologia , Miocárdio/enzimologia , Piridazinas/farmacologia , Tromboxano-A Sintase/antagonistas & inibidores , Animais , Ácido Araquidônico , Ácidos Araquidônicos/metabolismo , Plaquetas/ultraestrutura , Epoprostenol/biossíntese , Microssomos/metabolismo , Coelhos , Radioimunoensaio , Tromboxano A2/biossíntese
3.
Artigo em Inglês | MEDLINE | ID: mdl-7824529

RESUMO

A novel series of (6-aryl-4-oxo-pyrazolo 2,3-d] [1,2,5] triazin-3-yl) alkanoic acids was synthesized and evaluated in vitro as thromboxane A2 (TXA2) biosynthesis inhibitors. The experiments were carried out using arachidonic acid (32.8 microM) as a substrate and horse platelet microsomes (HPM) as sources of TXA synthetase. TXB2, a stable breakdown product of TXA2, was determined by radioimmunoassays (RIA). The substances under study, at concentrations ranging from 1.10(-6) M to 1.10(-4) M, significantly inhibited the biosynthesis of TXA2 in vitro. This activity was found to be dose-dependent, the potency of which could be related to structural features of the molecules. Compound 3b, bearing a butanoic side chain in the 3-position and a 4-chloro phenyl ring in the 6-position of the bicyclic system, was the most active derivative in in vitro enzyme inhibition (ID50 = 2.81 x 10(-5) M). Comparison of the spatial configurations of prostaglandin H2 (PGH2 and 3b displayed a good correlation between essential structural moieties of both molecules. In addition, conceptual model for the PGH2 and TX synthetase interactions was applied to compound 3b.


Assuntos
Tromboxano A2/biossíntese , Triazinas/farmacologia , Animais , Ácido Araquidônico/metabolismo , Plaquetas/metabolismo , Plaquetas/ultraestrutura , Relação Dose-Resposta a Droga , Cavalos/sangue , Microssomos/metabolismo , Modelos Moleculares , Prostaglandina H2 , Prostaglandinas H/metabolismo , Relação Estrutura-Atividade , Tromboxano B2/análise , Tromboxano-A Sintase/metabolismo , Triazinas/síntese química , Triazinas/química
4.
Artigo em Inglês | MEDLINE | ID: mdl-9223653

RESUMO

New series of 5-benzyl-6-methyl-4-oxo pyridazin-2-yl alkanoic acids, N-[(pyridazin-2-yl)alkyl] succinyl and glutaryl amides have been synthesized and evaluated in vitro as TXA2 biosynthesis inhibitors. The experiments were carried out using arachidonic acid (32.8 microM) as a substrate and horse platelet microsomes as sources of TXA2 synthase. The presence of TXB2, a stable metabolite of TXA2, was determined by RIA. The potency of active compounds (1.10(-4) < IC 50 < 1.10(-6) M) greatly depends on the length of the chain at the N-2 position on the pyridazine ring. Furthermore, enzyme inhibition in vitro is increased with the presence of a halogen atom on the aromatic moiety of the benzyl group at C-5. Compound 4f having a pentanoic side chain and a 4-fluoro benzyl moiety was the most active derivative with an IC50 value of 6.69 x 10(-6) M. Molecular modelling studies were done on all the synthesized pyridazinones and on prostaglandin H2 (PGH2) suggesting spatial features and volumes of TXA2 synthase pharmacophore mode in these series of derivatives.


Assuntos
Piridazinas/química , Piridazinas/farmacologia , Tromboxano A2/biossíntese , Amidas/síntese química , Amidas/química , Amidas/farmacologia , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Cavalos , Técnicas In Vitro , Microssomos/efeitos dos fármacos , Microssomos/metabolismo , Modelos Moleculares , Estrutura Molecular , Piridazinas/síntese química , Relação Estrutura-Atividade , Tromboxano-A Sintase/antagonistas & inibidores
8.
C R Acad Hebd Seances Acad Sci D ; 284(16): 1601-4, 1977 Apr 25.
Artigo em Francês | MEDLINE | ID: mdl-406086

RESUMO

Corticoadrenal extract has been shown to antagonize the action of prostaglandin E2 (Pg E2) on smooth muscle: this effect is noteworthy. It could partly elucidate the mechanism of the antihypotensive action of corticoadrenal extract.


Assuntos
Corticosteroides/farmacologia , Músculo Liso/efeitos dos fármacos , Prostaglandinas E/antagonistas & inibidores , Animais , Relação Dose-Resposta a Droga , Contração Muscular/efeitos dos fármacos , Ratos , Estômago
9.
Pharmacology ; 15(4): 341-7, 1977.
Artigo em Inglês | MEDLINE | ID: mdl-896951

RESUMO

The cardiovascular action of substance P (SP) has been studied in anaesthetized dogs. An analeptic respiratory and hypotensive action has been noted. The chronology of both effects would suggest that SP could be rapidly metabolized. The action of SP on respiration and general metabolism could be attributed either to one of its metabolites or to a secondary effect. It has not yet been stated to which mechanism--enzymatic or hormonal--it might be due.


Assuntos
Sistema Cardiovascular/efeitos dos fármacos , Substância P/farmacologia , Animais , Metabolismo Basal/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Débito Cardíaco/efeitos dos fármacos , Cães , Feminino , Coração/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Masculino , Consumo de Oxigênio/efeitos dos fármacos , Respiração/efeitos dos fármacos
11.
Prostaglandins Leukot Med ; 26(1): 21-32, 1987 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-3468520

RESUMO

As an experimental model, we used 6-week-old genetically obese-hypertensive rats (SHR-fa/fa) which were obtained by transferring the fatty/fa gene of hyperlipaemic obese rats into the genome of the SHR strain: the SHR-fa/fa were bigger and more hypertensive than their SHR littermates. Studying the capacity of the hearts, kidneys, spleens, brains and lungs to synthesize PGE2, PGF2 alpha and TXA2, enabled us to show that the hearts and lungs of SHR-fa/fa synthesized more PG than those of SHR; SHR-fa/fa brains generated less icosanoids than those of SHR; the amounts of PGE2 and TXA2 produced by the kidneys are similar in SHR and in SHR-fa/fa. From the experimental data we can infer that the introduction of the fatty/fa gene into the genome of SHR does not significantly alter the capacity of the kidneys to synthesize icosanoids; the more severe hypertension in the SHR-fa/fa would result from an increase in TXA2 biosynthesis by cardiac tissue which, at the same time, synthesized more PGE2, which could be a means of defence against hypertension. Moreover this genetical manipulation inhibited the icosanoid-synthesizing capacity of the brain which thus attenuated the central nervous system activity of the animals.


Assuntos
Hipertensão/metabolismo , Obesidade/complicações , Prostaglandinas E/biossíntese , Prostaglandinas F/biossíntese , Tromboxano A2/biossíntese , Animais , Encéfalo/metabolismo , Dinoprosta , Dinoprostona , Feminino , Hipertensão/genética , Rim/metabolismo , Pulmão/metabolismo , Microssomos/metabolismo , Miocárdio/metabolismo , Obesidade/genética , Obesidade/metabolismo , Ratos , Ratos Endogâmicos SHR , Baço/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA